The ongoing clinical trial NCT05619016 described above in the context of HER2-low breast cancer imaging also includes a cohort of patients with gastroesophageal cancer with known and unknown HER2-status for imaging with [68Ga]Ga-ABY-025 PET/CT. Here, ERBB2 is linked to breast cancer.